Successful second Sunshine C-Pulse implant
01 August, 2005 by Graeme O'NeillThree days after the death of the first patient to be implanted with its C-Pulse heart-assist pump, Sunshine Heart (ASX:SHC) has announced that a second patient has been successfully implanted with the device in a two-hour operation at New Zealand's Auckland City Hospital.
Science Industry Action Agenda endorsed by government
29 July, 2005 by Susan WilliamsonThe federal government endorsed the recommendations of the Science Industry Action Agenda Measure by Measure report on July 12, giving the go ahead for the eight recommendations made in the report to be implemented.
In Brief: Bioprospect, pSivida, CollTech, Prana, BresaGen, Sirtex, ChemGenex
29 July, 2005 by Staff WritersSelwyn Snell has resigned as the CEO and a director of BioProspect (ASX:BPO), after three years with the company.
First US sale for USCOM
28 July, 2005 by Helen SchullerSydney-based devices company USCOM (ASX:UCM) has received its first US orders for its heart monitoring equipment.
Iatia achieves positive quarter
27 July, 2005 by Ruth BeranMicroscopy company Iatia (ASX:IAT) will achieve its first positive operating cash flow quarter for the period ended June 30.
CSL deal boosts GroPep profits
27 July, 2005 by Ruth BeranAdelaide-based GroPep's (ASX:GRO) net profit after tax for the 2004-2005 financial year has been boosted by a one-off tax benefit of AUD$3.4 million, and is now expected to be approximately $6.4 million compared with a previous estimate of $3 million.
In brief: Psivida, Eqitx, Ellex, BRC, AFT
26 July, 2005 by Ruth BeranFollowing its recent Nasdaq listing, Psivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has appointed the president and CEO of New Jersey-based Chugai Pharma USA, David J Mazzo, as a non-executive director.
Consolidation and review for Avastra
25 July, 2005 by Ruth BeranWith the suspension of its Australian BioWeld Tube clinical trial and the postponement of European clinical trails, the June quarter was one of consolidation and review for Sydney biomaterials company Avastra (ASX:AVS).
Progen offered $3.39 million AusIndustry grant
25 July, 2005 by Ruth BeranBrisbane cancer-drug developer Progen Industries (ASX:PGL, NASDAQ:PGLAF) has been offered and intends to accept a AUD$3.39 million AusIndustry "Commercial Ready" grant for further development of the company's drug discovery program over the next three years.
Compumedics earnings lower than anticipated
22 July, 2005 by Ruth BeranCompumedics' (ASX:CMP) has reported revenues of AUD$38 million for the 2004-2005 financial year, with the company's audited results anticipated to be released during the second half of August.
Visiomed awarded $40,000 in WA government funding initiative
22 July, 2005 by Helen SchullerPerth-based biomedical devices developer, Visiomed Group (ASX:VSG) has been awarded two Business Development and Skills Training Scheme (BDSTS) grants, worth a total of AUD$40,000 from the Western Australian Department of Industry and Resources.
Biosignal technology effective against microbrial corrosion
22 July, 2005 by Graeme O'NeillBacteria and fungi thrive in some of the most hostile environments on the planet, and employ exotic metabolic reactions to extract energy from the most toxic substrates -- including acidic industrial wastes and hydrocarbon fuels.
International linkage grants and international fellows announced
21 July, 2005 by Graeme O'NeillFederal science minister Dr Brendan Nelson announced today the government will provide AUD$2,972,440 to fund 42 new awards for Australian-based researchers to participate in joint research projects with their overseas peers in 18 different countries, under the Australian Research Council's Linkage International Scheme.
BresaGen nets $200,000 SA govt grant
20 July, 2005 by Helen SchullerBresaGen (ASX:BGN) has been awarded a Commercial Infrastructure Grant of AUD$200,000 from Bio Innovation SA, the South Australian government's biotechnology agency.
Chemeq subscribers agree to extend convertible bond completion date
20 July, 2005 by Ruth BeranFollowing a trading halt, Chemeq (ASX:CMQ) has updated the market on the allotment and issue of AUD$20 million additional convertible bonds to Japanese investment group Mizuho International and related entities of investment management group Stark Investments, due on July 15.
